Reaction profile
The FDA adverse-event record for lack of efficacy (neoplasia, partial remission)
105 FDA adverse-event reports reference lack of efficacy (neoplasia, partial remission) (VeDDRA 2892). Plate codes and volume neighbourhood below; species, breeds, and drugs follow.
- #1369 of 2,481
- by report volume (all reactions)
- 105
- reports citing this reaction
- 3.8%
- death-coded share
- Dog
- most-affected species
Release-over-release change
What changed in the latest FDA data snapshot
PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Lack of efficacy (neoplasia, partial remission) has 105 reports now versus 96 in that prior snapshot: 9 more (9.4%).
- Report change
- +9
- Death-coded reports
- +1
- Death-coded share
- +0.7 pts
This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.
Subscribe to Lack of efficacy (neoplasia, partial remission) changesFDA AER · VeDDRA plate
Code 2892 VOL-LOW
VOL-LOW · DEATH-LOW · MID-PACK · PHOTO-FINISH · SPECIES-DOG · DRUG-LEAD · DESK-WIDE · BOOK-FULL
- VOL-LOW 105 reports
- DEATH-LOW 3.8%
- MID-PACK #1369/2481
- PHOTO-FINISH Decreased mean corpus…
- SPECIES-DOG Dog · 105
- DRUG-LEAD Tigilanol Tiglate · 79
- DESK-WIDE 20 breeds
- BOOK-FULL 8/8 fields
Nearest volume peer: Decreased mean corpuscular haemoglobin concentration (MCHC) (±0 reports)
Instrument codes from this reaction’s FDA CVM adverse-event extract: volume band, death-coded share, corpus rank, photo-finish peer, lead species, lead drug, breed desk, and book completeness. Not a clinical diagnosis.
Report-volume neighbourhood around Lack of efficacy
Highest and lowest poles plus nearest volume peers, not a full 2,500-reaction corpus board reprint.
Lack of efficacy (neoplasia, partial remission): low death-coded share in the FDA AER plate
Signature read: Lack of efficacy (neoplasia, partial remission)'s 3.8% death-coded share is among the lowest in the openFDA reaction corpus. Report volume sits in the middle third of the reaction corpus. Death-coded share is lower-third: 4 of 105 reports (3.8% of named reports). Nearest volume peer: Decreased mean corpuscular haemoglobin concentration (MCHC) (±0 reports). Lead species Dog (105). Lead co-reported drug Tigilanol Tiglate (79).
Read these counts as reporting volume, not risk: per our methodology, Lead co-reported drug Tigilanol Tiglate appears in filings alongside this reaction; that is association, not causation. Browse the full reactions index or the about page for how PlainBreed frames FDA CVM extracts.
Species Most Affected
Breeds Most Affected
Associated Drugs
Nationwide reactions with similar profiles
Two openFDA-derived peer sets for Lack of efficacy (neoplasia, partial remission), both floored at ≥50 reports so the neighborhoods stay in the advertised mass (the volume chart above is the unfloored photo-finish strip).
Similar report volume
Nearest other reactions by FDA report count (105 here).
Similar death-coded share
Nearest other reactions by death-coded share (3.8% here), distinct from the volume row.
What to do with this reaction
- Compare Lack of efficacy's report profile against similar reactions nationwide. See similar reactions
- Read how death-coded share differs from a mortality rate before drawing conclusions. Understanding adverse events
- Browse the full reaction directory to compare report counts across reaction types. All reactions
A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.
Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025
Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →